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ABSTRACT. The goal of radiotherapy is to achieve uniform target coverage while
sparing normal tissue. In proton therapy, the same sources of geometric uncertainty are
present as in conventional radiotherapy. However, an important and fundamental
difference in proton therapy is that protons have a finite range, highly dependent on
the electron density of the material they are traversing, resulting in a steep dose
gradient at the distal edge of the Bragg peak. Therefore, an accurate knowledge of the
sources and magnitudes of the uncertainties affecting the proton range is essential for
producing plans which are robust to these uncertainties. This review describes the
current knowledge of the geometric uncertainties and discusses their impact on proton
dose plans. The need for patient-specific validation is essential and in cases of complex
intensity-modulated proton therapy plans the use of a planning target volume (PTV)
may fail to ensure coverage of the target. In cases where a PTV cannot be used, other
methods of quantifying plan quality have been investigated. A promising option is to
incorporate uncertainties directly into the optimisation algorithm. A further
development is the inclusion of robustness into a multicriteria optimisation framework,
allowing a multi-objective Pareto optimisation function to balance robustness and
conformity. The question remains as to whether adaptive therapy can become an
integral part of a proton therapy, to allow re-optimisation during the course of a
patient’s treatment. The challenge of ensuring that plans are robust to range
uncertainties in proton therapy remains, although these methods can provide practical
solutions.
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The ability to create and deliver the ideal treatment
plan, where the target volume receives 100% of the
prescribed dose and normal tissue receives 0%, is the
holy grail of radiation therapy [1]. It is, however,
impossible to achieve this perfect balance. Instead,
multiple trade-offs are required to achieve a clinically
acceptable plan, so the problem becomes one of
optimisation. There are many factors that can affect
how ‘‘optimised’’ a patient’s treatment can be. This
review focuses on the challenges of proton therapy plan
optimisation, particularly in regard to range uncertain-
ties, and how to incorporate them into the plan
evaluation and verification process.
The nature of proton therapy makes the aim of cure
without complications potentially more achievable,
owing to the highly localised deposition of dose in the
characteristic Bragg peak [2]. This relates predominantly
to the ability to deliver high doses of radiation close to
normal tissue structures, which would be dose limiting
in conventional X-ray treatments, and to the finite range
of protons, which results in a reduced integral dose to
surrounding normal tissues.
From a clinical perspective, the exact role of proton
therapy has yet to be defined. However, for childhood
cancers, proton therapy delivers a lower dose to tissues
around the tumour than X-rays, resulting in less growth
disturbance and lower risk of secondary malignancies.
There is also the suggestion that the use of proton therapy
can reduce impairment of neuropsychological and intelli-
gence quotient development [3]. In adults, proton therapy
seems particularly effective in the treatment of radio-
resistant tumours close to critical structures such as the
brain stem and spinal cord. For example, outstanding
results have been published for the use of proton therapy
in the treatment of chordoma and chondrosarcoma [4]. The
current evidence for the use of proton therapy at different
sites has been extensively reviewed [5–8]. However, it will
also be important to consider expanding potential indica-
tions where logic and dosimetry indicate that proton
therapy can confer an advantage [7]. Although clinical
results comparing proton therapy with the most modern
X-ray therapy are currently lacking, overall clinical out-
comes are promising for both delivery options and
support the rationale for proton therapy [8]. The reader
is referred to the literature [9–11] for more clinical data.
Nevertheless, substantial opportunity for further clinical
research development and evaluation remains.
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The choice of treatment delivery can have a large
impact on the ability both to produce conformal dose
distributions and to produce a plan which is robust to
uncertainties. There are three main treatment delivery
techniques used clinically: passive scattering [12], uni-
form scanning and active scanning [13, 14] (Table 1).
These techniques are used to broaden the narrow proton
beam created by the accelerator into one that can achieve
a uniform dose coverage of the target at all depths. This
is achieved for passive scattering and uniform scanning
through the delivery of so-called spread-out Bragg peaks
(Figure 1).
Orthogonal to the beam direction, the beam is spread
using carefully designed scatterers (for passive scatter-
ing) or by continually deflecting the proton beam in
a regular pattern orthogonal to the beam direction
with constant intensity (uniform scanning). For both
approaches, three-dimensional (3D) conformation of the
final dose to the target is achieved through the additional
use of patient- and field-specific collimators (which
conform the dose in directions orthogonal to the beam)
and compensators (which conform the dose in the beam
direction) inserted in the beam nozzle [14]. Active
scanning, on the other hand, also uses magnets to scan
the proton beam across the target volume, but, in
contrast to uniform scanning, allows the fluence (dose)
applied at each Bragg position to be continuously varied.
Active scanning can offer an advantage to the patient by
allowing for greater flexibility in the delivered dose and
a reduction in integral dose to healthy tissues. It also
allows for the delivery of intensity-modulated particle
therapy (IMPT) [15], which is analogous with intensity-
modulated radiotherapy treatment (IMRT) in conven-
tional radiotherapy. Although there is, in principle, a
continuum of solutions to the IMPT problem, at its
extremes, IMPT can be divided into two ‘‘flavours’’:
distal-edge tracking (DET) [16], where Bragg peaks are
placed only at the edge of the target volume, and 3D
Table 1. Proton beam delivery techniques, production methods and planning techniques (the further down the table, the more
conformal the technique)
Methods of producing a
clinical proton beam to treat
entire target volume
Descriptions
Passive scattering Works on the principle that high atomic number materials, such as lead, scatter the beam with
minimum energy loss and low atomic number materials, such as plastic, decrease proton
energy with minimum scatter. Combining these materials to produce patient-specific
collimators and compensators results in a conformal treatment beam with a spread-out
Bragg peak
Uniform scanning This is similar to passive scattering with the difference that the beam is spread in the lateral
direction through magnetically deflecting the beam with constant fluence instead of using a
scattering foil. Different spot weights are produced using a compensator, as in passive
scattering
Active scanning This uses magnetic fields to deflect the path of each proton beam towards the planned position
in the target volume. Individual Bragg peaks are distributed within the target volume and the
cumulative effect produces an effective SOBP without the need for compensators. This is
achieved by either continuous magnetic scanning or spot scanning. The latter is analogous to
the step-and-shoot mode in IMRT, i.e. a non-continuous delivery of dose, where the exact
position is determined before the dose is delivered
Methods of achieving
adequate dose distributions
Descriptions
SFUD Single individually optimised proton fields that each deliver a homogeneous dose to a volume.
If necessary, these can be combined by simple addition
Field patching The sharp distal edge dose gradient can be matched up to the lateral edges of another ‘‘patch’’
field to produce a continuous dose distribution. Where possible, equivalent opposite fields
are also used to reduce the potential for dose variation at the abutting edges. Multiple fields
in patch work can be used to achieve multiple dose gradients inside a treatment volume. Field
patching is a 3D extension of matching lateral field edges. Therefore, if multiple fields are
used, each one can deliver a homogeneous dose to part of the volume
IMPT IMPT is analogous to IMRT, and is a mode of treatment delivery achievable only with active
scanning beams. IMPT uses narrow proton beams which are magnetically moved over the
volume in the transverse plane while the energy and intensity are altered to control dose to a
point and sculpt the dose at depth. Unlike SFUD treatments, IMPT can deliver a number of
non-uniform fields to produce the desired dose distribution
‘‘Flavours’’ of IMPT Descriptions
3D IMPT This is most similar to IMRT. Bragg peaks are placed throughout the entire volume and their
weights optimally adjusted
DET DET is a method by which pristine Bragg peaks of optimal weights are distributed only along the
distal edge of the target and not throughout the target volume
3D, three-dimensional; DET, distal-edge tracking; IMPT, intensity-modulated particle therapy; IMRT, intensity-modulated
radiotherapy treatment; SFUD, single-field uniform dose; SOBP, spread-out Bragg peak.
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IMPT [15], where Bragg peaks are optimally distributed
and weighted throughout the target volume (Figure 1).
IMPT allows for delivery of single inhomogeneous but
optimised fields to produce a final inhomogeneous dose
distribution in the target volume. This permits the
planner to be more flexible in the placement of residual
dose to healthy tissues. However, although IMPT offers
greater optimisation of dose delivery at the planning
stage, it has the potential to be sensitive to range
uncertainties [17, 18]. Table 1 summarises all these
modes of producing and manipulating proton dose
distributions.
Uncertainties in proton planning
Sources of uncertainty present in conventional radio-
therapy also apply to proton therapy. Most geometrical
uncertainties can be managed in the same way,
including variation in delineation, set-up uncertainties,
imaging inaccuracies and patient motion. However,
there exists an important and fundamental difference in
proton therapy—the proton range. Protons have a finite
range, highly dependent on the electron density of the
material they are traversing, resulting in a steep dose
gradient at the distal edge of the Bragg peak.
Positioning of these dose gradients is critical to
successful planning and treatment. Therefore, an uncer-
tainty of even a few millimetres can lead to under-
dosage in the target volume or overdosage of an organ
at risk (OAR).
Several authors have addressed the problem of range
uncertainties in proton therapy, and the purpose of this
section is to analyse their conclusions. Understanding the
causes and magnitude of range uncertainties and
incorporating them into the planning process is essential
for optimised proton planning.
Sources of range uncertainty
The main factors leading to range uncertainty are
shown in Figure 2. Because the main advantage of using
protons in cancer treatment is their finite range, this
advantage can be fully exploited only if the proton range
in the patient can be precisely predicted [19]. It has been
suggested that range uncertainties can be between 1 and
15mm for lung tumours [20], but larger changes are
possible owing to anatomical changes in the patient (e.g.
weight loss or gain and differential filling of anatomical
cavities). Uncertainties are normally compensated for in
X-ray radiotherapy by introducing safety margins around
the treatment volume and around OARs to produce a
planning target volume (PTV) and planning OAR volume
(PRV), as recommended by the International Committee
on Radiation Units and Measurements (ICRU) Reports 50
and 62 [21, 22]. A similar method has been recommended
by the ICRU for protons [23]. The larger the safety margin,
the less conformal the resulting dose distribution.
Therefore, to achieve an optimum proton treatment plan,
the range prediction needs to be as accurate as possible.
The variables that give rise to uncertainties in the
range prediction (Figure 2) can be divided into two main
groups: those causing uncertainties in the range calcula-
tion in the treatment planning system (TPS), and those
leading to discrepancies between planning dose and
delivered dose.
Range calculation in the treatment planning system
Inaccuracies arising from the planning CT
With respect to range calculation uncertainties, these
can arise from inaccurate data exported to the TPS. CT is
used to acquire patient image data and the Hounsfield
units (HUs) are then converted into proton-stopping
(a) (b) (c)
Figure 1. Schematic of Bragg peak delivery along a single profile through a target. (a) A flat spread-out Bragg peak (SOBP) is
achieved by placing spots with increasing weights throughout the target to produce a uniform field, as used in passive
scattering and single-field uniform dose. (b) Only the most distal single pristine Bragg peak (BP) is used for distal-edge tracking.
(c) Optimally weighted spots are positioned throughout the volume to achieve fields with non-uniform doses for three-
dimensional intensity-modulated particle therapy.
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powers so dose calculations can be made. Errors arise in
proton range calculation from CT-based plans owing to
inaccuracy in the HU to proton stopping power conver-
sion and inaccuracies in the HU values themselves [24].
Inaccuracies in the HU values are caused by noise, CT
artefacts and beam hardening.
Schaffner and Pedroni [25] and Espan˜a and Paganetti
[20] investigated how the conversion of HUs to stopping
power affects the range calculation in comparison with
the real treatment range. Espan˜a and Paganetti [20]
tested different conversion methods, including the
traditional stoichiometric calibration method. Positron
emission therapy (PET) imaging was used to determine
the range of the proton beam in a phantom and compare
it with the calculated range. It was noted that the back-
to-back photons imaged with PET are generated from
electron–positron annihilations caused by inelastic
nuclear interactions between protons and target nuclei
and not from atomic interactions, which primarily leads
to dose deposition. Espan˜a and Paganetti [20] and
Schaffner and Pedroni [25] both concluded the same
result: that the uncertainty caused by conversion was
,¡1%. There is research being undertaken into the
development of proton CT. This would remove the
uncertainty in the conversion from HUs to proton-
stopping powers and enable image guidance with the
patient set-up for treatment [26].
Noise is a stochastic error that either adds or subtracts
from the HU value; this type of error is important only if
the proton beam is sensitive enough to be affected by
these changes in HU value. It was concluded that errors
caused by noise have a similar contribution to conversion
uncertainties: ,¡1% [25]. Beam hardening had a greater
effect on the assigned HU value. This was dependent on
the position and density of the tissue and added errors of
the order of ¡1.8% and ¡1.1% for bone and soft tissue,
respectively [25].
It is essential for CT-scanner-specific calibrations to
be carried out [23, 25]. This is because, even though
stopping power is independent of proton energy and the
position of the target, HUs are dependent on the X-ray
spectrum and target position. Each scanner will produce
a different X-ray spectrum generated with a different
tube potential and current, therefore requiring indivi-
dual calibration. Moyers et al [27] carried out the
measurement of the relative linear stopping powers of
21 different tissue substitutes. These were then scanned
using both kilovoltage and megavoltage CT and the
relationship between stopping power and HU value was
determined.
Lomax [28] has described how the combined effects of
the proton’s sharp distal fall-off, finite range and multiple
Coulomb scattering can have an impact on the sensitivity
of plans to density heterogeneities in the patient. The Paul
Scherrer Institute in Switzerland has biologically cali-
brated its CT scanner to have an accuracy of 1% for soft
tissue and 2% for bony tissue, but, owing to inherent
errors such as beam hardening, reconstruction artefacts
and reconstruction algorithms [28], it has been stated that
an error in HU value of 3% is more realistic. To investigate
the effect of this error, each plan was recalculated with the
HU value increased and decreased by 3% to simulate an
undershoot and overshoot scenario. The results were
obtained for a simple prostate case and a skull base case.
The distal-edge tracking (DET) approach was found to
incur a systematic over- and underdosage of the clinical
treatment volume (CTV) of ,5% when a ¡3% HU error
was introduced, whereas the 3D IMPT dose–volume
histogram (DVH) for the nominal, under- and overshoot
plans showed little difference.
Figure 2. Schematic of sources of range uncertainties in proton radiotherapy. HU, Hounsfield unit; TPS, treatment planning
system.
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Inaccuracies arising from the dose calculation
algorithm
Lomax [19] investigated the limitations in analytical
dose calculations and the effects of uncertainties in
density calculation from CT data in DET and 3D IMPT
dose distributions. To investigate errors arising from
using an analytical dose calculation algorithm the dose
distributions for Version 1 and Version 2 DET and 3D
IMPT skull base plans were compared with the same
plans calculated using Monte Carlo models (Version 1
plans use less stringent constraints on OARs than
Version 2 plans). In contrast to using an analytical
mathematical algorithm to calculate dose distributions,
Monte Carlo models use a probability distribution to
model interactions and the production of secondary
particles in a medium for a given energy. For the skull
base case the two calculation methods were in close
agreement for an acceptance level of ¡10%, but
decreased for lower acceptance levels. At all acceptance
levels, 3D IMPT plans showed better agreement in the
PTV than DET plans, with 87% of points in the 3D IMPT
plan agreeing to within ¡3% and only 80% of points
agreeing to within ¡3% in the DET plan for Version 1
plans. However, for the Version 2 plans, agreement falls
to 77% and 70% for 3D IMPT and DET, respectively. In
the OARs it was found that the Monte Carlo calculation
predicted smaller doses in the optic nerve and brain stem
than the analytical calculation, especially in the Version 2
plans. The trend showed that for both cases 3D IMPT
showed smaller differences than the DET plans. It was
concluded that DET IMPT was relativity sensitive to
calculation errors; in comparison, 3D IMPT was more
robust with respect to both types of error.
Discrepancies between planned dose and delivered
dose
Despite algorithms being able to calculate range in the
presence of density heterogeneities, range uncertainties
can be introduced by geometric changes in the position
of density heterogeneities relative to the proton beam by
set-up errors and patient motion [16].
Motion
In many treatment sites, organ motion has to be
considered and incorporated into the planning and
delivery workflow. Organ motion includes interfraction
motion (i.e. between each fraction) and intrafraction
motion (i.e. during the treatment delivery). Patient
motion influences the position of the interfractionally
moving organ and intervention in the form of immobi-
lisation and image guidance for precise bony or soft-
tissue anatomy set-up at the beginning of each fraction is
required to optimise treatment delivery and minimise
CTV to PTV margins. These are well-established techni-
ques in radiotherapy [29], so will not be discussed
further.
Intrafraction motion includes both interfield (i.e.
between each field) and intrafield (i.e. during the field)
motion. Intrafraction motion changes during the delivery
over the time period of seconds and minutes and
includes anatomical changes such as bowel movements,
respiration and heartbeats. Studies have been carried out
to determine the magnitude of inter- and intrafraction
motion at different tumour sites [30–32].
With proton therapy, geometric changes caused by
motion can also result in density changes, and therefore a
change in radiological path length, along the beam path.
In X-ray therapy, the dose distribution changes by only a
few per cent, owing to density changes. However, their
influence in proton therapy can result in severe under-
dosage of the CTV and overdosage of OARs and normal
tissues distal to the target [33]. This effect is the same for
both scattering and scanning delivery techniques. In
addition, for active scanning, the major effect of intra-
field motion is ‘‘interplay’’, which relates to motion,
usually respiratory motion, with a frequency similar to
that of the scanned beam, and which can lead to over-
and underdosage in the target volume [34–37].
Lomax [19] investigated the effects of interfraction,
intrafraction and interfield motion for both 3D and DET
IMPT treatment plans. It was reported that, for a 5-mm
shift in the dose distribution, an underdosage of up to
20% can occur in the CTV when plan optimisation for
maximum OAR sparing is used. Treatment deliveries
involving high dose gradients that rely on matching
contributing fields are very sensitive to any changes in
position between deliveries of each field. An important
conclusion from this paper is that for certain IMPT plans
a simple PTV margin cannot be applied to compensate
for interfraction motion. Further investigation into the
management of uncertainties and more assessment for
IMPT treatments at the treatment planning level are
needed. Lomax [19] also described the greater sensitivity
protons have to density heterogeneities owing to their
physical characteristics and that these could accentuate
motion errors. Without a PTV, there is no method for
recording dose to a moving CTV or for evaluating plans
through the use of DVHs. Without a PTV, there is no
method for recording close to a moving CTV or for
evaluating plans through the use of DVH’s and for these
IMPT plans, no other compensation method to ensure
that the CTV is covered. After comparing the effects of
geometrical and density heterogeneities for both DET
and 3D IMPT it was found that DET plans are very
sensitive to motion errors and considerable changes in
the dose distribution were found. The reasoning behind
this is that internal dose gradients in the individual fields
in DET can cause large variations in dose within the
target volume when mismatched. This was observed for
interfield motions, but would also be an issue when
intrafield motions were present.
Simulations have also been carried out by Lambert et
al [33], albeit only in homogeneous geometries, to
investigate how interplay affects the dose distribution
in the CTV. Lambert et al took the ICRU 50 [21]
recommendations for PTV dose homogeneity of 95–
107% as threshold. Their results showed that in extreme
cases up to 100% of the target volume received doses
below that recommended by ICRU 50 and with a
minimum dose as low as 34% of the prescribed dose.
These results were backed up by simulations carried out
by Gro¨zinger et al [38] and experimental work by Bert et
al [39]. Bert et al carried out the first patient simulation
that confirmed underdosage using four-dimensional
computed tomograph (4DCT) lung data. Despite using
Treatment planning optimisation in proton therapy
Br J Radiol, 86, 20120288 5 of 12
margins that consider the effect of the changing radio-
biological path length, adequate CTV coverage could not
be achieved.
There also exists a related range uncertainty owing to
the relative biological effectiveness (RBE) of proton
beams, which is beyond the scope of this review. For
more information on RBE the reader is referred to the
literature [40–43].
Managing uncertainties including positional
discrepancies and motion
The management of uncertainties is critical to success-
ful radiotherapy. Current methods of reducing geometric
uncertainties include immobilisation, in-room imaging,
image guidance, planning from 4D CT and gated
radiotherapy for respiratory motion. These are all
methods that are routine in X-ray therapy and are now
being applied to proton therapy [44].
Motion mitigation
Two main methods of motion mitigation have been
developed for active scanning to mitigate the effects of
interplay: rescanning (repainting) and beam tracking [44].
Rescanning
Typically in proton therapy, multiple dose ‘‘painting’’
is required to deliver the prescribed dose distribution to
each layer of the target volume. In IMPT, the dose is
delivered from multiple directions by a number of fields
and with a range of different proton energies to produce
a uniform dose distribution throughout the target
volume. To increase dose conformity, steep dose
gradients are used at the target border and field edges.
This increases the complexity of the fluence maps per
field and therefore makes the plan less robust to
uncertainties. Intrafraction motion can lead to an under-
and overdose pattern that is dependent on the motion
parameters (initial phase, period and amplitude) and the
speed of the scanning process or direction of scanning.
By rescanning the PTV several times per treatment
fraction an averaging effect of the over- and underdose
pattern can be achieved. As long as the intrafraction
motion changes between each rescan, so that there is no
synchronisation between delivery and organ motion, a
homogeneous dose distribution to the CTV can be
achieved with a ‘‘blurred’’ dose distribution in the
region of the margins [44]. There are two main types of
rescanning:
N rescanning by energy slice, also known as slice-by-
slice, level painting or non-volumetric rescanning
N rescanning of volume, also known as volumetric
rescanning or uniform repainting.
The problem of organ motion and rescanning syn-
chronism has also been tackled by several groups,
including Furukawa et al [45] and Seco et al [37].
Solutions include:
N using random modulations, e.g. a change in scan
speed
N repainting energy slices in different orders (random
repainting)
N random delays between repaints (time delay)
N change in scan paths between two rescans
N use of data from motion monitoring systems in
combination with modulation dose rate, either as
phase-controlled rescanning or as breath-sampled
rescanning.
Data from phase-controlled rescanning and breath-
sampled rescanning show that uniform spreading of
rescans over the motion of the breathing cycle leads to
more robust treatment delivery, requiring fewer rescans
than the other methods for the same level of homo-
geneity in the CTV. There are also two methods of
delivering rescanned treatments [35]:
N Scaled rescanning—this is delivering each rescan with
a proportionally reduced dose per scan and is the
most typical method.
N Isolayered rescanning—where a specified number of
protons per spot are delivered at each scan, which
leads to a different spot position in each rescan. This is
because some spots will have received sufficient dose
from previously completed scans.
Beam tracking
With beam tracking [44], the motion of the CTV is
monitored and compensated for so that a PTV margin is
reduced. Owing to the need to compensate for both CTV
motion and the change in radiological path length in
proton therapy, the German national heavy-ion physics
laboratory, the Gesellschaft fu¨r Schwerionen, in
Darmstadt, has established a method of using a motor-
driven compensation system for changes in radiological
path length [46, 47] and raster scanning [45, 48].
Margins
In X-ray radiotherapy, the PTV is used to provide the
safety margins for all uncertainties in planning and
delivery [21, 22]. The objective with current X-ray
technology is to deliver a dose between +7% and 25%
of the prescribed dose, with dose coverage which is as
uniform as possible. Geometric uncertainties owing to
positional discrepancy or motion are unavoidable.
Random uncertainties act to ‘‘blur’’ the distribution
while systematic uncertainties shift the entire dose
distribution [49]. A shift in the cumulative dose
distribution can result in part of the target being missed
and potential overdose to normal tissue.
The widely used CTV–PTV margin recipe, derived by
van Herk [50], is used to ensure that 90% of patients have
CTV coverage of at least 95% of the prescribed dose. The
static PTV represents the moving CTV and is therefore a
useful method of evaluating a plan, by using DVHs to
report the minimum dose to the CTV. In proton therapy,
if conventional PTV margins do not produce plans
robust to uncertainties, another method of ensuring
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confidence in a planned dose distribution representing
the delivered dose distribution is required. This can be
achieved by increasing margins or ‘‘smearing’’ the
proton range with a compensator in the case of passive
scattering. However, this will lead to a reduction in dose
conformity in the plan. The concept of a safety margin
also partly fails for set-up errors because they not only
shift the dose distribution but also change the range
where there are density changes in the beam path,
leading to a distorted dose distribution [51]. In proton
therapy, any concept used to compensate for organ
motion-generated uncertainties must include both geo-
metric motion and the influence it has on the beam
range, as this can have a severe dosimetric impact [51].
PTV margin sizes in proton therapy have been
investigated by Thomas [52]. In many comparative
studies of achievable dose distributions between protons
and X-rays, the CTV and PTV margin sizes are the same
for both modalities. The CTV and OAR volumes are
invariably the same for any treatment modality.
However, the size of the margin between CTV to PTV
and OAR to PRV is modality dependant. Thomas [52]
quantified margins required for PTVs and PRVs in
proton therapy for anterior single, anterior–posterior
parallel opposed and four-field brick proton beam
arrangements. Each type of systematic and random error
was considered and the effect they had in geometry and
range was discussed, as was the modality dependency.
The key message is that isodoses defined by lateral
edges, for instance, can be treated in the same way as for
X-rays, whereas isodoses defined by the distal edge will
have a different uncertainty arising from inaccurate
electron densities derived from CT data. Margins were
calculated for a head and neck (H&N) and a prostate
case. For the H&N case the CTV–PTV margins in all
three planes for the single field and parallel opposed
fields were smaller than those required by X-rays;
however, they were greater for the four-field brick plan.
This same pattern was observed for the prostate case.
This is because a smaller margin size is needed in the
anterior–posterior direction for single and parallel
opposed (3mm compared with 10.5mm for the H&N
case), as set-up errors and motion in this direction will
not affect the dose distribution.
Albertini et al [53] addressed the issue of whether
safety margins in proton planning are necessary. In this
paper two types of treatment delivery were investigated:
single field uniform dose (SFUD) plans and IMPT plans.
Plans included:
(i) an SFUD plan to the PTV
(ii) an IMPT plan delivering uniform fields to the PTV
(iii) a non-uniform field IMPT plan, with strict
constraints on OARs, planned to the PTV
(iv) a non-uniform field IMPT plan, with strict
constraints on OARs, planned to the CTV.
The robustness of each plan to random set-up and
systematic range uncertainties was compared.
Robustness was determined using the concept of ‘‘error
bar dose distributions’’, by shifting dose distributions
relative to the expected errors and then displaying a final
‘‘error bar’’ dose distribution and ‘‘error bar’’ volume
histogram; therefore, it was representative of the possible
discrepancies in dose between planning and delivery.
The results from this work show that, for uniform field
deliveries [(i) and (ii)], the use of margins improved the
plan robustness, where ,5% of the CTV contained errors
.10%. However, in highly complex non-uniform IMPT
plans [(iii) and (iv)], margins improved robustness only
marginally and, for 5% of the CTV, errors of up to 55%
were observed. For plans (iii) and (iv), steep dose
gradients existed within the target, leading to uncertain-
ties within the target. Because margins can help CTV
coverage only at the edges of the target volume and not
in the centre, they have little effect on plan robustness
when steep dose gradients exist within the target volume
[53]. It was found, however, that complex IMPT plans
were robust to OARs when they were included in the
optimisation as a constraint. It was concluded that there
is a need for more sophisticated methods for taking into
account uncertainties in highly modulated IMPT plans,
such as including them in the optimisation. This work
assumed that the set-up uncertainty was indeed random
and considered only the systematic component of the
range error. It did not include the effect on the dose
distribution from motion uncertainties.
Optimisation functions for robust proton planning
An alternative to using margins is being developed by
incorporating errors directly into the optimisation algo-
rithm, as proposed by Unkelbach et al [54] and
Pflugfelder et al [55]. This can be implemented because
in IMPT there exist many solutions which are all
dosimetrically equivalent. This ‘‘degeneracy’’ of solu-
tions can be used to reduce the sensitivity of the plan to
uncertainties if they are incorporated into the optimisa-
tion process [55].
Unkelbach et al [54] investigated methods for incor-
porating range uncertainties into the treatment planning
process and simulated doses for a non-patient case. The
two approaches taken were the probabilistic approach
and robust linear programming. The first assumed prior
knowledge of the probability distribution of the uncer-
tainty; in most cases, the distribution was assumed
normal. The latter optimised the worst case that could
have occurred. The optimisation used by the Deutsches
Krebsforschungszentrum (Heidelberg, Germany) in-
house TPSs for particle therapy (KonRad, Heidelberg,
Germany), is the worst-case dose distribution approach
[55]. The worst-case dose distribution was introduced by
Lomax et al [56] and is a method of combining multiple
dose distributions into a single one. For a voxel inside the
target volume the minimum dose to this voxel is stored
and for a voxel outside of the target volume the
maximum dose is stored. Each voxel is treated indepen-
dently so the worst-case dose distribution is an ‘‘unphy-
sical’’ one. Although the worst-case dose distribution is
unphysical it can be used as a lower bound for the worst-
quality treatment plan. A best-case plan can be seen as
the upper bound in the same respect, but to the best
achievable plan quality. In this optimisation it is
assumed that the range uncertainties for each Bragg
peak are correlated, so that at the target the range
uncertainty is accumulated and effects within the target
are ignored. The dose from each beamlet was calculated
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at multiple ranges; three ranges between 2 and 5mm
were used, and these were the nominal, maximum and
minimum range uncertainties [56]. The set-up uncer-
tainty was modelled as a shift of the target inside a
sphere with a radius equal to the maximum set-up
uncertainty. They concluded that both methods led to
treatment plans less sensitive to range variations and that
both plans were of a similar quality. This was achieved
by using the lateral edge instead of the distal edge to
shape the dose distribution at the transition between the
OAR and the tumour for both methods.
Pflugfelder et al [55] applied the worst-case optimisa-
tion method to real patient data where the target
surrounded the spinal cord. Uncertainties of the beamlet
ranges of ¡5mm were considered. The range uncer-
tainty was sampled at three positions: the nominal range,
the maximum range and the minimum range. Using this
optimisation process, the plan’s sensitivity to range
uncertainties was decreased. However, this was
achieved by compromising the dosimetric quality of
the plan by:
(i) using the lateral instead of the distal edges of the
Bragg peaks to shape the dose gradients between
the target and the OAR
(ii) adding a ‘‘safety margin’’ automatically at the distal
field edge for each treatment beam
(iii) flattening the dose profile in depth for each
treatment beam compared with the nominal plan.
For the tumour, the largest deviations between
delivered and prescribed doses corresponded to an
underdosage close to the OAR, whereas the deviations
in most other parts of the tumour were small. The
maximum doses delivered to OAR voxels reached
approximately 80% of the prescribed dose [55]. The
DVHs from each method showed very similar results.
This group [55] showed comparable results to those of
Unkelbach et al [54] using their worst-case optimisation
function; owing to the simplicity of the worst-case
optimisation, it was expected to be faster [55]. When
using the worst-case optimisation incorporating both set-
up and range uncertainties, the resulting change to the
dose distribution was such that the distal dose gradient
of the treatment beam was smoothed.
Chen et al [57] introduced a method of including
robustness into a multicriteria optimisation (MCO)
framework for IMPT. In current inverse planning
systems for IMRT the dose distribution is determined
by a computerised optimisation based on dose prescrip-
tions for targets and other volumes which have been
assigned an importance level [58]. To determine the plan
quality, a number is assigned based on the deviation
from prescription dose in each volume and the optimisa-
tion result is the plan with the lowest number. This is a
trial and error process, given that the resulting plan may
not be clinically acceptable and the importance levels
assigned to each volume may need adjusting and the
optimisation rerun. This can be time consuming and the
best-quality plan may not have been achieved as the
planner cannot try every combination of parameters.
There also exists a problem that, if upper and lower
constraints are met, the optimisation process will not
further improve doses to these volumes. This means that
IMRT and IMPT cannot be exploited to their full
potential owing to limitations with inverse planning
[58]. The concept of multi-objective Pareto optimisation
(often known as MCO) has been introduced into radio-
therapy treatment planning to overcome these problems
[59]. A Pareto optimal treatment plan is not a single plan
but a database of plans where each one represents a
Pareto optimal solution which cannot be improved
without worsening at least one other parameter [58]. In
this case the planner can navigate through the pre-
calculated database of Pareto optimal plans and visualise
in real time the trade-offs for each case [60]. MCO allows
for the plan which strikes the best balance between
different objectives to be selected from a Pareto front.
Chen et al [57] suggested that the trade-off between
robustness and dosimetric quality in IMPT can be
investigated using MCO. An example is shown in
Figure 3. A planning objective for robustness represents
the worst case realised for any error scenario and so can
provide a measure of plan robustness. The MCO method
used by this group was based on a linear projection
solver using ‘‘minimax’’ optimisation, meaning that the
objective was minimised for the worst-case error
scenario and was used to investigate plan robustness to
uncertainties. The computing time required for the
robustness optimisation for each Pareto optimal plan
was 5min. Range uncertainties have been modelled
using an overshoot and undershoot scenario of ¡3%, as
used by Lomax [28]. The set-up uncertainty was
modelled using discrete rigid shifts of the patient with
respect to the isocentre. A base of skull tumour was
Figure 3. Illustrating two para-
meters for optimisation, conformity
and robustness, and how a Pareto
front can be used to investigate
clinically achievable plans with the
same Pareto-optimised solution, but
with different values of importance
on robustness and conformity.
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planned twice: once using robust optimisation (but
without MCO) and once with margins. A chordoma
case was planned with MCO as an ideal example of the
trade-off between brain stem sparing, CTV coverage and
robustness. In the skull base case the DVH of the CTV for
both the robust plan and the margin plan showed similar
coverage for the nominal plan. However, once plans with
errors were introduced, the coverage was worse for the
margin case. In consideration of brain stem sparing the
robust plan ensured that in all error cases the dose was
limited to 60Gy; this was not seen in the margin plan. In
the chordoma case the Pareto surface of objectives
allowed the planner to have greater control when
deciding between a robust plan, a conformal plan or
somewhere in between.
Treatment analysis and validation
For all areas in radiotherapy, validation and quality
assurance are routinely carried out. Phantom work and
technical assessment are carried out when a new
technology or method is being implemented, such as
motion mitigation techniques. However, patient-specific
quality assurance is also required, and this starts at the
decision to accept a given plan design. In cases where
margins are in use, the PTV is used as a tool for reporting
the minimum dose to the CTV. If the PTV method is to be
discarded then a new method for recording dose to a
moving CTV, and for evaluating plans through the use of
DVHs, is needed. As discussed above, Albertini et al [61]
have devised a possible solution to this problem by
determining plan robustness for set-up and range errors
using an error bar dose distribution method. This
method was later validated experimentally using a
customised anthropomorphic phantom based on a
diagnostic head phantom, and GafChromicH EBT2 batch
F100070903B film, to carry out patient-specific quality
assurance under realistic conditions and with deliber-
ately introduced errors. A large part of ensuring
optimum treatment delivery to the patient is verifying
the accuracy of the dose delivered and comparing it with
that predicted by the planning system. In cases where
uniform fields are being delivered it is enough to
experimentally measure the individual field doses, and
in the case of proton therapy, the dose in homogeneous
water [61]. The highly modulated nature of IMPT means
that ever more complex methods of plan verification are
being developed to cope with the advancing treatment
technology to ensure safe patient treatment. Safai et al
[62] described how a scintillation dosimetry system was
used to verify such proton treatments. The problem with
this method was that, even though it could accurately
measure the dose delivered, the dose from the TPS
needed to be recalculated in a homogeneous material to
be compared with the measured results [61]. This
approach of patient-specific plan verification is not
adequate when fields of inhomogeneous dose distribu-
tions are being applied. Each inhomogeneous dose
distribution will, in combination, achieve a uniform dose
in the target volume, but any slight misalignment of a
steep dose gradient could lead to a severe under- or
overdosage in comparison with the plan [61]. This
effect could be worsened by the presence of density
heterogeneities in the patient [61]. By using the custo-
mised phantom, Albertini et al [61] have been able to
measure the accuracy of dose and the effect of spatial
and range errors by deliberately introducing errors. Set-
up errors were introduced by moving the phantom by
known amounts, and range errors simulated by modify-
ing the HU values by ¡3% [19]. From this work it was
found that 3D IMPT plans were more robust than DET
plans. The theory is that there are fewer Bragg peaks
used in DET, whereas in 3D IMPT more spots are used
(,180 for DET compared with ,1500 for 3D IMPT in the
example used), each with a lower weighting than those
in DET, so that that any misalignments would have a
greater impact on the DET plan.
Discussion
To produce optimal plans using protons, knowledge of
the proton range in the patient is essential. There aremany
factors that can contribute to range uncertainty. HU
uncertainties can contribute to approximately ¡3%
uncertainty in range even after site-specific CT scanner
calibrations have been carried out. Owing to the steep
dose gradients that can be achieved at the edges of, and
within, the target volume, precise field matching is
required to prevent over- or underdosage in the target.
Simulation and patient data examples have been used to
show that the use of a PTV margin does not ensure
uniform dose coverage to the CTV for complex IMPT
plans. Despite these results, there is still a need for facility-
based and treatment protocol-specific simulations to be
carried out to achieve quantitative assessments for
different tumour sites [44]. Parameters such as dose
regime, scan path pattern and beam extraction rate need
to be included because they will affect the resulting dose
distribution.
Methods of improving plan robustness to range
uncertainties beyond the use of margins are being
developed for use in complex IMPT plans to ensure
CTV coverage. However, all of these methods will
decrease the achievable conformity of a plan. Robust
optimisation using the worst-case scenario will produce
a robust plan, sacrificing conformity by placing a lateral
edge instead of the sharp distal edge to shape the dose
between the target and the OAR. The use of robust MCO
gives the planner greater control over objective weights.
This is important because there is little evidence or
known experience in determining what type of plan,
conformal or robust, is most beneficial for the population
of patients.
The difficulty with deliberately introducing uncertain-
ties into either the optimisation or the plan evaluation is
that all probability distributions are assumed to be
known. Albertini et al [53] and Chen et al [57] only
considered range uncertainties created in the range
calculation arm in Figure 2. The assumption is then that
any change in radiological path length caused by set-up
or motion, whether during a fraction or between
fractions, has a negligible effect on the range. Motion
errors will be dependent on anatomical location and set-
up error will be protocol specific, based on what image
guided radiotherapy treatment (IGRT) schedules are in
place and the type of immobilisation used. More research
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is needed in quantifying range uncertainties for different
anatomical locations so that they can be implemented
into the robust optimisation of dose modelling. This
would include investigating range errors associated with
different IGRT schemes, types of motion, and when to
use adaptive planning.
In the absence of a PTV, novel methods to evaluate
dose coverage have been developed such as the error bar
DVH and the use of worst-case and best-case optimisa-
tion to give upper and lower bounds on a DVH. A
challenge for all these methods will be how to carry out
adequate and efficient patient-specific verification.
Currently, studies on beam tracking and rescanning
have not been carried out using patient data. The data
available from non-patient heterogeneity studies have
shown that rescanning techniques produce improved
results compared with beam tracking, but further
investigations using real patient data are required [44].
There is no information in the literature regarding
patient-specific validation for rescanning and beam
tracking methods because they are not yet in routine
clinical use.
Adaptive radiotherapy is the adjustment during the
treatment course of the parameters initially chosen at
planning, in order to re-optimise the treatment as a
direct result of unavoidable changes in the patient. In
proton therapy, the use of adaptive therapy may prove
to be valuable for ensuring the delivered dose matches
the planned dose at each fraction. In this context,
access to high-quality daily volumetric imaging, and
fast-dose recalculation algorithms and computing
power, will be required. This may provide the
opportunity for greater individualisation of the
patient’s treatment. Use of a multi-objective Pareto
optimisation function could allow plans to be recalcu-
lated when necessary using different weights for
robustness and conformity, incorporating image gui-
dance data to optimise the plan.
A significant advantage of conventional X-ray therapy
over proton therapy is the wealth of experience and
knowledge available. A key area for optimising the
treatment planning process is in gaining experience in
planning proton treatments. The number of proton
facilities available worldwide is rapidly increasing, yet
there is a substantial shortage of oncologists, dosimetrists
and physicists with the required expertise [63]. In the
UK, patients have been able to access proton therapy
abroad under the auspices of the National Health Service
Proton Overseas Programme since 2008 [64], and the UK
government recently announced that two proton centres
will be established in England. It is hoped that these will
start to treat patients in the next 4–5 years [65, 66], such
that developments discussed here will be directly
relevant.
It has been shown that a PTV may not be the best
solution for ensuring target coverage in the case of
complex IMPT plans. This is the result of the sensitivity
of the proton range to density heterogeneities and the
achievable steep dose gradients inside the volume. Many
groups have been working towards possible solutions
for achieving dosimetric quality and plan evaluation
without a PTV. The solutions described here show great
promise for optimising proton therapy planning.
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